226 related articles for article (PubMed ID: 36634811)
21. Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat.
Sepehrvand N; Islam S; Dover DC; Kaul P; McAlister FA; Armstrong PW; Ezekowitz JA
J Card Fail; 2022 Aug; 28(8):1298-1308. PubMed ID: 35589087
[TBL] [Abstract][Full Text] [Related]
22. Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death.
McEvoy JW; Chen Y; Ndumele CE; Solomon SD; Nambi V; Ballantyne CM; Blumenthal RS; Coresh J; Selvin E
JAMA Cardiol; 2016 Aug; 1(5):519-28. PubMed ID: 27439107
[TBL] [Abstract][Full Text] [Related]
23. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
Coats AJS; Tolppanen H
Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114
[TBL] [Abstract][Full Text] [Related]
24. Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat.
Armstrong PW; Zheng Y; Troughton RW; Lund LH; Zhang J; Lam CSP; Westerhout CM; Blaustein RO; Butler J; Hernandez AF; Roessig L; O'Connor CM; Voors AA; Ezekowitz JA;
JACC Heart Fail; 2022 Sep; 10(9):677-688. PubMed ID: 36049817
[TBL] [Abstract][Full Text] [Related]
25. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
Kang C; Lamb YN
Am J Cardiovasc Drugs; 2022 Jul; 22(4):451-459. PubMed ID: 35624347
[TBL] [Abstract][Full Text] [Related]
26. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial.
Lam CSP; Mulder H; Lopatin Y; Vazquez-Tanus JB; Siu D; Ezekowitz J; Pieske B; O'Connor CM; Roessig L; Patel MJ; Anstrom KJ; Hernandez AF; Armstrong PW;
J Am Heart Assoc; 2021 Nov; 10(22):e021094. PubMed ID: 34743540
[TBL] [Abstract][Full Text] [Related]
27. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment.
Lupón J; de Antonio M; Galán A; Vila J; Zamora E; Urrutia A; Bayes-Genis A
Mayo Clin Proc; 2013 Mar; 88(3):234-43. PubMed ID: 23384388
[TBL] [Abstract][Full Text] [Related]
28. High-sensitivity cardiac troponin T levels and secondary events in outpatients with coronary heart disease from the Heart and Soul Study.
Beatty AL; Ku IA; Christenson RH; DeFilippi CR; Schiller NB; Whooley MA
JAMA Intern Med; 2013 May; 173(9):763-9. PubMed ID: 23568589
[TBL] [Abstract][Full Text] [Related]
29. Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction.
Myhre PL; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Beldhuis IE; Fleg JL; Lewis E; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
Circ Heart Fail; 2018 Nov; 11(11):e005312. PubMed ID: 30571192
[TBL] [Abstract][Full Text] [Related]
30. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.
Myhre PL; Vaduganathan M; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
Circ Heart Fail; 2020 Jan; 13(1):e006638. PubMed ID: 31957468
[TBL] [Abstract][Full Text] [Related]
31. Vericiguat for the treatment of heart failure with reduced ejection fraction.
Siddiqi AK; Greene SJ; Fudim M; Mentz RJ; Butler J; Khan MS
Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):245-257. PubMed ID: 36881733
[TBL] [Abstract][Full Text] [Related]
32. Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial.
Senni M; Lopez-Sendon J; Cohen-Solal A; Ponikowski P; Nkulikiyinka R; Freitas C; Vlajnic VM; Roessig L; Pieske B
ESC Heart Fail; 2022 Dec; 9(6):3791-3803. PubMed ID: 35880474
[TBL] [Abstract][Full Text] [Related]
33. Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial.
Pocock SJ; Ferreira JP; Gregson J; Anker SD; Butler J; Filippatos G; Gollop ND; Iwata T; Brueckmann M; Januzzi JL; Voors AA; Zannad F; Packer M
Eur Heart J; 2021 Nov; 42(43):4455-4464. PubMed ID: 34423361
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model.
Aulin J; Hijazi Z; Lindbäck J; Alexander JH; Gersh BJ; Granger CB; Hanna M; Horowitz J; Lopes RD; McMurray JJV; Oldgren J; Siegbahn A; Wallentin L;
Am Heart J; 2022 Sep; 251():13-24. PubMed ID: 35569564
[TBL] [Abstract][Full Text] [Related]
35. Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study.
Jia X; Buckley L; Sun C; Al Rifai M; Yu B; Nambi V; Virani SS; Selvin E; Matsushita K; Hoogeveen RC; Coresh J; Shah AM; Ballantyne CM
Eur J Prev Cardiol; 2023 Nov; 30(16):1731-1740. PubMed ID: 37306504
[TBL] [Abstract][Full Text] [Related]
36. N-Terminal Pro B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T Levels Are Related to the Extent of Hibernating Myocardium in Patients With Ischemic Heart Failure.
Zelt JGE; Liu PP; Erthal F; deKemp RA; Wells G; O'Meara E; Garrard L; Beanlands RSB; Mielniczuk LM
Can J Cardiol; 2017 Nov; 33(11):1478-1488. PubMed ID: 28966019
[TBL] [Abstract][Full Text] [Related]
37. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Armstrong PW; Pieske B; Anstrom KJ; Ezekowitz J; Hernandez AF; Butler J; Lam CSP; Ponikowski P; Voors AA; Jia G; McNulty SE; Patel MJ; Roessig L; Koglin J; O'Connor CM;
N Engl J Med; 2020 May; 382(20):1883-1893. PubMed ID: 32222134
[TBL] [Abstract][Full Text] [Related]
38. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
[TBL] [Abstract][Full Text] [Related]
39. Impact of diabetes on the predictive value of heart failure biomarkers.
Alonso N; Lupón J; Barallat J; de Antonio M; Domingo M; Zamora E; Moliner P; Galán A; Santesmases J; Pastor C; Mauricio D; Bayes-Genis A
Cardiovasc Diabetol; 2016 Nov; 15(1):151. PubMed ID: 27809845
[TBL] [Abstract][Full Text] [Related]
40. Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial.
Gravning J; Askevold ET; Nymo SH; Ueland T; Wikstrand J; McMurray JJ; Aukrust P; Gullestad L; Kjekshus J;
Circ Heart Fail; 2014 Jan; 7(1):96-103. PubMed ID: 24284025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
